A new drug, NXP800, shows promise in treating hormone therapy-resistant prostate cancer by targeting the Heat Shock Factor 1 (HSF1) pathway, which supports cancer cell growth.

"Prostate cancer: Three drug trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith ...

In the lab, the researchers found that NXP800 slowed the growth of prostate cancer cells—even for cells which were resistant to the hormone therapy enzalutamide. In biopsies of patients with ...

The main finding of the observational study, published in the journal Neurology, suggests that alpha-blocker drugs used to treat urinary symptoms caused by an enlarged prostate gland may reduce ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

but their optimal use—such as which drug or drug combinations should be used first to achieve the best outcomes from prostate cancer treatment—is still being worked out. Nevertheless ...

Scientists are trialling an innovative new drug that could offer hope to patients with advanced prostate cancer, particularly those for whom current treatments have ceased to be effective.

Brain metastases from prostate cancer (PC ... Furthermore, docetaxel (the drug of choice for the first-line treatment of castration-resistant PC) cannot cross the blood–brain barrier and ...

The new urine test looks at 18 genes that are linked to high-risk prostate cancer. Previous research showed that MPS2 could ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.